← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	3,160	-35	-1%	$202B
2	2 Eli Lilly LLY $1.13T	2,446	+103	+4%	$256B
3	3 Amgen AMGN $238B	2,353	+17	+0.7%	$101B
4	4 Becton Dickinson BDX $52.5B	1,535	-42	-3%	$61.5B
5	5 McKesson MCK $116B	1,165	+27	+2%	$40.9B
6	6 Regeneron Pharmaceuticals REGN $83.1B	1,064	-31	-3%	$55B
7	7 AstraZeneca AZN $260B	1,016	+33	+3%	$35B
8	8 Novo Nordisk NVO $174B	932	+31	+3%	$16.4B
9	9 Conagra Brands CAG $6.83B	791	+40	+5%	$13.8B
10	10 ResMed RMD $33.8B	677	-5	-0.7%	$20.3B
11	11 West Pharmaceutical WST $26.9B	655	-61	-9%	$20.6B
12	12 Lamb Weston LW $7.41B	557	+30	+6%	$9.14B
13	13 DELISTED CATALENT, INC. CTLT	544	+8	+1%	$19.7B
14	14 Embecta EMBC $369M	483	+446	+1,205%	$1.38B
15	15 DaVita DVA $11.9B	462	-48	-9%	$6.53B
16	16 Teva Pharmaceutical Industries Limited TEVA $48.3B	456	+18	+4%	$3.8B
17	17 Inspire Medical Systems INSP $1.99B	287	-12	-4%	$5.01B
18	18 Medifast MED $137M	284	-4	-1%	$1.75B
19	19 BellRing Brands BRBR $1.04B	276	+23	+9%	$2.76B
20	TWNK 20 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	253	+3	+1%	$3.04B
21	21 Accendra Health ACH $23.6M	249	-16	-6%	$2.47B
22	22 Opko Health OPK $1.23B	231	+2	+0.9%	$480M
23	23 Amphastar Pharmaceuticals AMPH $1.14B	223	+20	+10%	$1.06B
24	24 Herbalife HLF $1.52B	204	-25	-11%	$2.05B
25	25 DELISTED WW International WW	192	-21	-10%	$449M